Aprepitant Shortage: What Providers and Prescribers Need to Know in 2026

As an oncologist, anesthesiologist, or prescriber involved in chemotherapy or surgical care, you've likely fielded patient calls about difficulty filling Aprepitant prescriptions. While oral Aprepitant is not formally listed on the FDA shortage database as of early 2026, real-world availability at retail pharmacies remains inconsistent — and that inconsistency has direct clinical implications for antiemetic prophylaxis.

This briefing covers the current supply landscape, prescribing considerations, cost and access issues, and practical tools to help you keep your patients covered.

Timeline: How We Got Here

Aprepitant has experienced supply variability in recent years:

• 2022-2023: IV Fosaprepitant (Emend for injection) experienced manufacturing-related supply disruptions, shifting demand toward oral capsules and the newer injectable alternatives Cinvanti and Aponvie
• 2024: Generic oral Aprepitant from multiple manufacturers (Sandoz, Glenmark, and others) helped stabilize oral supply, though spot shortages at individual pharmacies continued
• 2025-2026: Oral generic supply is generally adequate at the wholesale level, but distribution allocation policies and low retail stocking continue to create patient-facing gaps. IV formulation availability has improved with additional products (Cinvanti, Aponvie) entering the market

The net result: the supply exists, but the last mile to patients — particularly those filling prescriptions at retail pharmacies rather than oncology specialty pharmacies — remains uneven.

Prescribing Implications

Inconsistent Aprepitant availability creates several clinical considerations:

Timing-Sensitive Prescribing

Aprepitant must be taken 1 hour before chemotherapy (Day 1: 125 mg, Days 2-3: 80 mg). Any delay in filling the prescription can mean a patient arrives for chemotherapy without their NK1 antagonist on board. Consider:

• Sending prescriptions to the pharmacy at least 7 days before the scheduled cycle
• Using e-prescribing to reduce processing delays
• Noting on the prescription that this is a time-sensitive chemotherapy support medication

Generic vs. Brand Considerations

Prescribe generic Aprepitant by default unless there's a clinical reason for the brand. Generic availability is significantly better and pricing is far more accessible — approximately $25 with discount programs versus $180-$500+ for brand-name Emend. If you prescribe Emend by brand and don't authorize generic substitution, some pharmacies may not be able to fill it.

Route Flexibility

When oral Aprepitant is unavailable, keep these alternatives in your prescribing toolkit:

• Fosaprepitant 150 mg IV — single-dose prodrug that replaces the full 3-day oral regimen. Administered 30 minutes before chemotherapy
• Cinvanti (Aprepitant injectable emulsion) — can be given IV push over 2 minutes or as a 30-minute infusion. Available in 130 mg/18 mL and 32 mg/4.4 mL vials
• Aponvie (Aprepitant injectable emulsion) — another IV alternative for patients who cannot take oral formulations

If your clinic stocks any of these, they can serve as a seamless backup when patients can't fill oral prescriptions.

Current Availability Picture

Based on available data as of March 2026:

• Generic oral Aprepitant capsules: Generally available through major wholesalers (McKesson, AmerisourceBergen, Cardinal Health). Spot shortages at individual pharmacies occur but are usually resolvable within 1-3 days
• Emend (brand oral): Available but less commonly stocked at retail pharmacies due to cost differential. Prior authorization requirements on many formularies add friction
• Fosaprepitant (IV): Supply improved from 2022-2023 lows but still variable. Check with your facility pharmacy
• Cinvanti / Aponvie: Generally available through specialty distributors. Heron Therapeutics offers Heron Connect support services for Cinvanti access

Cost and Access Landscape

Cost remains a significant access barrier for some patients, particularly the uninsured and underinsured:

• Generic Aprepitant: ~$100 retail; $25-$30 with discount programs (GoodRx, SingleCare, RxSaver)
• Brand Emend: $180-$500+ cash price
• Insurance coverage: Most commercial and Medicare Part D plans cover generic Aprepitant on Tier 2-3. Brand may require step therapy or prior authorization
• Patient assistance: The Merck Patient Assistance Program (merckhelps.com) provides free Emend to qualifying uninsured patients. Heron Connect offers support programs for Cinvanti

When discussing cost with patients, consider directing them to savings resources. Our patient-facing guide on saving money on Aprepitant covers coupons, discount cards, and assistance programs.

Tools and Resources for Providers

Medfinder for Providers

Medfinder helps providers and care teams check real-time Aprepitant availability at pharmacies in the patient's area. You can use it to:

• Verify stock before sending a prescription to a specific pharmacy
• Identify alternative pharmacies with availability
• Share availability results directly with patients

Prescribing Alternatives

If Aprepitant (oral or IV) is unavailable, evidence-based NK1 antagonist alternatives include:

• Akynzeo (Netupitant 300 mg / Palonosetron 0.5 mg) — single oral dose covers both NK1 and 5-HT3 pathways. Also available IV as Akynzeo IV
• Varubi (Rolapitant 180 mg) — single oral dose with a 180-hour half-life and minimal CYP3A4 interaction. May be preferred in patients on complex medication regimens

For a patient-oriented overview of alternatives, see alternatives to Aprepitant.

Prior Authorization Resources

If brand-name Emend or Cinvanti requires prior authorization:

• Heron Connect provides PA support forms and sample appeal letters for Cinvanti
• Most payer PA forms for NK1 antagonists require documentation of chemotherapy emetogenicity level and prior antiemetic use
• For Medicare patients, note that IV formulations may be covered under Part B (medical benefit) when administered in the clinic

Looking Ahead

The antiemetic landscape is relatively stable heading into the remainder of 2026. Multiple generic manufacturers continue to produce oral Aprepitant, and the availability of multiple IV formulations (Fosaprepitant, Cinvanti, Aponvie) provides prescribers with route flexibility they didn't have a few years ago.

Key actions for your practice:

1. Prescribe generically to maximize patient fill rates and minimize cost
2. Send prescriptions early — at least 7 days before chemotherapy
3. Stock IV alternatives in your clinic as backup
4. Use Medfinder to verify availability before routing prescriptions
5. Connect patients with cost resources — merckhelps.com, GoodRx, SingleCare

Final Thoughts

Aprepitant availability in 2026 is adequate at the wholesale level but inconsistent at the pharmacy counter. As prescribers, we can bridge this gap by prescribing generically, planning ahead, maintaining IV alternatives, and leveraging tools like Medfinder to ensure our patients have uninterrupted access to antiemetic prophylaxis.

For the patient-facing version of this update, see Aprepitant shortage update: what patients need to know in 2026.